用户名: 密码: 验证码:
针药结合治疗前列腺增生症(湿热挟瘀证)的临床研究
详细信息    本馆镜像全文|  推荐本文 |  |   获取CNKI官网全文
摘要
本研究拟采用针药结合疗法治疗慢性前列腺增生患者,期望借此研究能开拓该病治疗的有效途径,为目前在人群中发病率较高的慢性前列腺增生提供一种新的安全有效的治疗方案。
     目的
     本课题采用临床随机对照研究,观察温针灸结合中药治疗中医辩证属湿热挟瘀证的慢性前列腺增生症,与单纯中药组为对照,以期证实温针灸治疗前列腺增生症虚症的确切疗效。
     方法
     采用随机对照方法,将入选的72例慢性前列腺增生症患者,按1:1对照原则分为试验组、对照组各36例,试验组采用温针灸+中药(前列康片)口服,操作方法:主穴:肾俞,大肠俞、秩边;配穴:中极,关元,水道,三阴交。主穴为每次必取穴位,其余穴位随症加减。主穴行温针灸,其余配穴只行针刺得气后留针。先取背俞穴位常规消毒后,手持直径0.35mm×40mm毫针,快速直刺进针,施以平补平泻的手法得气后,于针柄加上1.5cm艾柱,温针灸1~3壮,并依每个患者不同症状给予随症配穴;当所有艾柱烧尽清除灰烬后出针,再取腹部俞穴位常规方法操作。口服中药(前列康片):前列康片(普乐安片)为片剂:0.5g/片,60片/瓶,口服,5片/次,3次/日。病人在服药期间不得服用对主症主病起治疗作用的其他药物。一周为一个疗程,连续四个疗程后观察疗效。对照组采用口服中药(前列康片)治疗。疗效指标观测:(1)临床症状、体征、舌象、脉象等;(2)IPSS:排尿通畅情况,排尿时间,夜尿数等;(3)排尿症状对生活质量的影响(L);(4)肛门指检情况;(5)肾、膀胱、前列腺B超检查;(6)尿流动力学检查;(7)血清前列腺特异性抗原(PSA)测定(必要时做);观察时间:以上各项实验室指标均在纳入病例前及试验结束时进行,其余各项每周观察记录一次。
     结果
     本研究共有合格受试者72例,治疗组36例,对照组36例;均为门诊病人。西医诊断为前列腺增生症,中医辨证为湿热挟瘀证。合格病例随机分为温针灸结合中药治疗组(简称试验组)和中药治疗组(简称对照组),各36例。
     患者基线特征的可比性分析:治疗前,两组性别、年龄、病程构成情况、I-PSS前列腺症状评分、生活质量、排尿状况、小腹症状、最大尿流率、残余尿量、排尿时间、前列腺直肠指诊分级、尿频、尿急、排尿费力等临床症状以及舌象、脉象等比较,差异均无统计学意义。提示影响两组资料组间均衡性较好,具有可比性。
     中医症状疗效比较:治疗组临床控制率为22.22%,显效率为25.0%,有效率为41.67%,总有效率为88.89%;对照组临床控制率为8.33%,显效率为13.89%,有效率为63.89%,总有效率为86.11%。两组总疗效等级差异比较(Ridit分析,z=1.99,P<0.05),差别有统计学意义。提示治疗组疗效优于对照组。两组总显效率(临床控制率+显效率)比较,差异有统计学意义(χ2=4.96,P=0.025<0.05)。提示治疗组的总显效率(47.22%)高于对照组(22.22%)。
     国际咨询委员会推荐标准疗效比较,治疗组显效率为37.4%,有效率为48.7%,总有效率为86.1%;对照组显效率为26.0%,有效率为50.0%,总有效率为76.0%。两组比较,差异有统计学意义。
     两组治疗后病情程度改善情况比较,差异有统计学意义(Z=1.99,P=0.045)。两组治疗后I-PSS前列腺症状评分改善程度比较,差异有统计学意义(Z=2.04,P=0.040)。两组治疗后生活质量改善程度比较,差异有统计学意义(Z=1.97,P=0.04)。
     两组治疗后排尿状况改善程度比较,差异有统计学意义(Z=2.03,P=0.04)。两组治疗后小腹症状改善程度比较,差异有统计学意义(Z=1.99,P=0.04)。两组治疗后最大尿流率改善程度比较,差异无统计学意义。两组治疗后残留尿量减少程度比较,差异有统计学意义(Z=2.24,P=0.02)。
     两组治疗后前列腺体积缩小程度(优:前列腺体积治疗后前比值460%;良:前列腺体积治疗后前比值≤80%;中:前列腺体积治疗后前比值≤90%;劣:前列腺体积治疗后前比值>90%)比较,差异无统计学意义。
     两组治疗后排尿时间缩短程度比较,差异有统计学意义(Z=1.97,P=0.04)。两组治疗后小腹症状、尿频比较,差异有统计学意义。
     两组治疗后排尿状况、口苦、口粘、口渴不欲饮、尿急、排尿费力、夜尿多比较,差异无统计学意义。两组治疗前后最大尿流率差值比较(组间比较),差异无统计学意义。治疗组治疗前后最大尿流率比较,差异有统计学意义(t=2.10,P=0.03)。对照组治疗前后最大尿流率比较,差异有统计学意义(t=2.85,P=0.00)。两组治疗前后平均尿流率差值比较(组间比较),差异无统计学意义。治疗组治疗前后平均尿流率比较,差异有统计学意义(t=2.56,P=0.01)。对照组治疗前后平均尿流率比较,差异有统计学意义(t=1.99,P=0.04)。
     两组治疗前后排尿时间差值比较(组间比较),差异无统计学意义。治疗组治疗前后排尿时间比较,差异有统计学意义(t=3.36,P=0.00)。对照组治疗前后排尿时间比较,差异有统计学意义(t=2.11,P=0.03)。两组治疗前后残余尿量差值比较(组间比较),差异有统计学意义(t=3.22,P=0.00)。治疗组治疗前后残余尿量比较,差异有统计学意义(t=2.08,P=0.04)。对照组治疗前后残余尿量比较,差异无统计学意义。
     安全性检测:两组治疗前检测了血常规,大便常规,尿常规,肝功能(GPT),肾功能(BUN),(均在正常范围内),治疗后复查,均未见异常。
     用药后未观察到不良反应症状。
     结论
     治疗组临床控制率为22.22%,显效率为25.0%,有效率为41.67%,总有效率为88.89%;对照组临床控制率为8.33%,显效率为13.89%,有效率为63.89%,总有效率为86.11%。两组总疗效等级差异比较(Ridit分析,z=1.99,P<0.05),差别有统计学意义。提示治疗组疗效优于对照组。两组总显效率(临床控制率+显效率)比较,差异有统计学意义(χ2=4.96,P=0.025<0.05)。提示治疗组的总显效率(47.22%)高于对照组(22.22%)。临床症状、体征、尿流动力学检查疗效结果表明,两组治疗后病情程度、I-PSS前列腺症状评分、生活质量、排尿状况、小腹症状、最大尿流率、残余尿量、排尿时间、平均尿流率等,均有明显改善。治疗组治疗后前列腺增生患者病情程度、生活质量、排尿状况、小腹症状、残余尿量、排尿时间、平均尿流率等改善程度均明显高于对照组(P<0.05),而治疗组治疗后I-PSS前列腺症状评分、前列腺体积、最大尿流率等改善程度均与对照组相似(P>0.05)。提示针药结合治疗前列腺增生症,能明显改善患者的主要临床症状、体征及尿流动力学检查结果,其作用优于对照组。
     安全性检测结果表明,部分病人治疗前后血、尿、大便常规、肝功能(GPT)、肾功能(BUN)、心电图检测结果,未能提示针药结合治疗后对血液系统及心、肝、肾功能有损害。
     经温针灸结合中药治疗后,前列腺增生患者的临床症状明显改善,效果显著。研究结果初步证明了采用温针灸结合中药的方法治疗慢性前列腺增生虚证,可有效提高其临床疗效。结合临床,温针灸结合中药治疗组能解除尿路梗阻症状,疗效肯定,初步证明了采用温针灸结合中药的方法治疗慢性前列腺增生(湿热挟瘀证)可有效提高其临床疗效,值得推广。
Objective
     This randomized controlled clinical research adopts the clinical epidemiological methods, clinical research methods and statistical methods. It takes pure Chinese herbs therapy as comparison and observes the clinical curative effect of applying acupuncture and Chinese herbs to cure hyperplasia of prostate (moist heat and blood stasis). It discusses the difference of the clinical effect and provides the basis for the clinical treatment of hyperplasia of prostate.
     Methods
     The research has 70 patients of hyperplasia of prostate (moist heat and blood stasis), who were treated in Chinese Medicine clinic in Taiwan from February 2008 to February 2009 and who met the case selection standards.
     All the patients were divided into two groups (the warm needle acupuncture added Chinese herbs group, and pure Chinese herbs group), with 35 in each group at the rate of 1:1. The pure Chinese herbs group were treated with the QIANLIE KANG TABLETS, taking 2.5g a time, tid, P.O. The warm needle acupuncture added Chinese herbs group were treated with warm needle acupuncture and taking the QIANLIE KANG TABLETS the same way as the pure Chinese herbs group. A week was a course. All the patients were treated for four weeks. After every week, patients'clinical symptom, IPSS, PSA, quality of life, and urodynamic study, etc. were measured. Before and after the treatment, check the safety indexes.
     Use software EPIDATA 3.1 to set up the database and use software SPSS 15.0 for statistics and analysis. The measurement material is expressed by x±S and the numeration material by constituent percentage. For the interclass comparison of the measurement material, take F test (for heterogeneity, take Kruskal-Wallis H rank sum test); for the interclass multiple comparison, take q test (Newman-Keuls); for self circa comparison, take the t pair test or pair rank sum test. For the interclass comparison of the classified material, take x2 test. For the interclass comparison of the ranked material, use Kruskal-Wallis H rank sum test. Draw the statistics graphs with software Graph Pad Prism 4.03.
     Results
     This research collects 70 cases with no difference in two groups in age, course of disease, clinical symptom, IPSS, PSA, quality of life, and urodynamic study, etc.
     The warm needle acupuncture added Chinese herbs group has significant curative effect for hyperplasia of prostate (moist heat and blood stasis) treatment. The control rate is 22.2%; the efficient rate is 25.0%; the effective rate is 41.6%,;the total effective rate is 88.9%.
     According to the standard of international advisory council, the warm needle acupuncture added Chinese herbs group has more significant curative effect for hyperplasia of prostate (moist heat and blood stasis) treatment. The control rate is 37.4%; the efficient rate is 48.7%; the total effective rate is 86.1%.
     After the treatment, the patients'clinical symptom, IPSS, PSA, quality of life, and urodynamic study changes a lot. The therapy of warm needle acupuncture added Chinese herbs can effectively improve the patients' clinical symptom, urine condition, and quality of life, and lower the patients'residual urine volume and urine time. In a word, the therapy of warm needle acupuncture added Chinese herbs, has better effect than the therapy of pure Chinese herbs, and it is safe without side effect.
     Conclusion
     Based on the clinical results, the warm needle acupuncture added Chinese herbs therapy can cure the hyperplasia of prostate (moist heat and blood stasis) noticeably. It can adjust the patients'clinical symptom, urine condition, and quality of life, lower the patients'residual urine volume, and shorten the urine time. It is safe and has no side effect. It is an effective method for hyperplasia of prostate (moist heat and blood stasis) and deserves being popularized.
引文
[1]天津科学技术出版社编.实用男性学[M].天津科学技术出版社,1988:324.
    [2]李曰庆主编.前列腺疾病临床荟萃[M].第1版.北京:华夏出版社.1996:7-17.
    [3]曹开庸主编.中医男科现代研究[M].第1版.成都:四川科学技术出版社.1998:171-172.
    [4]戚世伟,熊成熙,郎笑梅.金匮肾气丸防治前列腺增生探析[J].中医药临床杂志.2004,16(5):499-450.
    [5]张氏,郑清国,陈光强.论命门即前列腺[J].福建中医学院学报,2005,15(5):45-46.
    [6]李彪.实用男科临床手册[M].第1版.北京:人民军医出版社.1995:158.
    [7]李卫真主编.前列腺病中医诊疗学[M].第1版,北京:北京科学技术出版社.1996:122-123.
    [8]吴光明,魏秋关.清热利湿化瘀法治疗前列腺肥大33例[J].湖南中医杂志.1993,9(3):36.
    [9]焦安钦.前列腺增生症病机特点与治疗思路[J].贵阳中医学院学报.1996,18(4):3-5.
    [10]周家珩.扶正化痰法治疗前列腺增生症135例[J],江苏中医.1991,12(3):115.朱永康.通闭汤治疗前列腺增生症[J].江苏中医.1991,12(11):32.
    [11]周安方,曹继刚.肾虚肝实是前列腺增生的基本病机探析[J].中医药学刊.2004,22(8):1372-1376.
    [12]张亚大,卢子杰.前列腺增生症病机与辨证分型相关性的临床研究[C].中国中西医结合学会泌尿外科专业委员会第三次全国学术会议论文汇编.2001,165-166.
    [13]张春和,李海松.李曰庆教授治疗前列腺增生症经验[J].中国临床医生.2003,31(10):56-57.
    [14]武传贵,孟繁荣.补肾化瘀通淋法治疗前列腺增生症84例[J].辽宁中医杂志.2004,31(6):489.
    [15]刘清国,王朝阳,李军.针刺治疗良性前列腺增生的临床研究.2003,23(4):200.
    [16]Yutaka K, Hiroaki M, Hiroshi T, etal. Transition zone index as a risk factor for acute urinary retention in benign prostatic hyperplasia Urology,1998,51.595-600.
    [17]刘跃新,陈山,张光银等.前列腺体积与移行带体积变化的年龄差异[J].中华泌尿外科杂志,2002,23:478-479.
    [18]李晓宝,张进生.良性前列腺增生诊治研究进展[J].中国微创外科杂志,2008,8(2):186-188.
    [19]莫乃新,戎亚雄,吕忠等.前列腺增生症与饮食的相关性研究[J].江苏医药.2003,29(12):921-922.
    [20]Sciarra F, Toscano V. Role of estrogens in human benign prostatic hyperplasia. Arch Androl,2000,44(3),213-220.
    [21]Carballido, Rodriguez, Rodriguez Vallejo, etal. Benign prostatic hyperplasia and evidence based medicine:its approach in clinical practice. Med Clin(Barc),2000,114 Suppl 2,96-104.
    [22]Steers WD.5alpha-reductase activity in the prostate. Urology,2001,58(6 Suppl 1),17-24.
    [23]Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol,2001,39(2),151-158.
    [24]Mochtar CA, Rahardj O D, Umbas R. A higher PSA density cut off level in patients with intermediate PSA values for the early detection of prostate cancer. Can To Kagaku Ryoho,2000,27 Suppl 2,514-522.
    [25]Hartmann RW, Reichert M. New nonsteroidal steroid 5 alpha-reductase in-hibitors. Syntheses and structure-activity studies on carboxamide pheny-lalky substituted pyridones and piperidones. Axch-Pharm-(Weinheim),2000,333(5),145-153.
    [26]Stattin P, Kaaks R, Riboli E, etal. Circulating insulin 7 like growth factor-I and benign prostatic hyperplasia-a prospective study. Scand J Urol Nephrol,2001,35(2)122-126.
    [27]Luo Jun, Dunn Thomas, Ewing Charles, etal. Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis Prostate,2002,51 (3):189-200.
    [28]贺大林.前列腺增生的病因学研究进展[J].临床外临床外科杂志.2005,13(2):72-74.
    [29]Shapira E,Hartanto V,Lepor H. Anti2desminvs anti2actin for quantifying the area density of prostate smooth muscle[J]. Prostatc,1992,20:259-262.
    [30]Kyprianou N, Litvak JP, Borkowski A, etal. Induction of prostate apoptosis by doxa2zosin in benign prostatic hyperplasia[J]. JUrol,1998,159:1810.顾方六.现代前列腺病学[M].北京:人民军医出版社出版,2002.171.
    [31]Hudson PB, Boake R, Trachtenberg J, etal. Effciency of finasteride is maintained inpatients with BPH treated for years[J].Urology,1999,53:690-695.
    [32]居小兵,吴宏飞,华立新等,爱普列特治疗良性前列腺增生的疗效观察[J].中华男科学,2002,8(1):42-44.
    [33]李茜,黄冬冬,杜冠华等.1-(2,6-二甲基苯氧基)-2-(3,4-二甲氧基苯乙氨基)丙烷盐酸盐对大鼠心脏α1受体的影响[J].中国药理学与毒理学杂志.1990,4(2):91-94.
    [34]郑恒,钱家庆,邵春丽等.1-(2,6-二甲基苯氧基)-2-(3,4-二甲氧基苯乙氨基)丙烷盐酸盐对大鼠膀胱内压及前列腺增生的作用[J].中国药理学与毒理学杂志.2001,15(2):150-154.
    [35]马庆杰,谷欣权,孔祥波等.90Sr/90Y前列腺增生治疗器(尿道型)的剂量分布及安全性研究[J].中国老年学杂志.2001,21(6):434-435.
    [36]孔祥波,谷欣权,何小东等.90Sr/90Y β射线腔内照射治疗前列腺增生症的临床应用研究[J].中国老年学杂志.2002,22(1):29-30.
    [37]王旭昀,赵增彬,商建伟等.前列腺增生症的中医药治疗[J].杏林中医药,2008,28(9):631-632.
    [38]张国铿.浅谈前列腺肥大症证治体会[J].新中医,1996,28(2):61.
    [39]董襄国,吴明清.良性前列腺增生辨证论治[J].中国医药学报,2004,19(6):358-359.
    [40]叶科贵.辨证论治前列腺增生症67例[J].河南中医,2006,26(7):43-44.
    [41]张亚大,卢子杰,张平等.益肾逐瘀汤治疗良性前列腺增生症100例疗效观祭及对性激素的影响[J].新中医.2003,35(9):14-15.
    [42]李龙骧.黄芪桂枝五物汤临床新用[J].吉林中医药,2007,27(11):45.
    [43]赵建业.戴春福教授以活血法治疗前列腺增生症经验[J].福建中医药,2004,35(2):21-22.
    [44]赵跃红.加味壮元汤治疗前列腺增生症62例[J].湖南中医杂志,2004,20(3):54.
    [45]张振卿.化痰祛瘀软坚化症法治疗前列腺增生症的体会[J].四川中医,2003,21(5):25-26.
    [46]李连贞.痰瘀同治法应用体会[J].吉林中医药,2001,21(2):4.
    [47]杨乾珽.通塞汤治疗良性前列腺增生症36例[J].天津中医药,2007,24(5):386.
    [48]武传贵,孟繁荣.补肾化瘀通淋法治疗前列腺增生症84例[J].辽宁中医杂志,2004,31(6):489.
    [49]黄小波,李宗信,李斌等.消癃合剂联合消癃散治疗良性前列腺增生症的临床研究[J].中国中西医结合急救杂志,2006,13(2):73-75.
    [50]贾永华,张延杰,周延生等.通癃胶囊治疗前列腺增生症的临床研究[J].南京中医药大学学报,2006,2(5):290-293.
    [51]刘敬松,宋伟,李烨等.前列金丹片治疗前列腺增生148例[J].山东中医杂志,2005,24(2):94.
    [52]孔飞,孙聪,陈光亮.中药治疗良性前列腺增生症的研究进展[J].云南中医学院学报,2008,31(4):67-70.
    [53]王宏志.癃闭舒胶囊治疗良性前列腺增生疗效观察[J].中华男科学杂志,2005,11(11):873.
    [54]张亚强.日本应用汉方药治疗前列腺增生的临床研究[J].国外医学中医中药分册,2000,22(3):145-147.
    [55]何本鸿.金匮肾气丸配合穴位针刺治疗良性前列腺增生的疗效观察[J].中华男科学杂志,2007,13(10):953-954.
    [56]陈通文,王文凤,邓春华等.前列通瘀胶囊治疗湿热瘀阻型前列腺增生症76例临床观察[J].亚太传统医药,2006,7:440-441.
    [57]向贵,薛波新,单玉喜等.中成药前Ⅰ号方治疗良性前列腺增生90例疗效观察[J].苏州大学学报(医学版),2007,27(5):822-823.
    [58]李祥光,鞠大宏,宋竖旗等.前列舒通对前列腺增生模型大鼠bcl-2表达的影响[J].中国中西药结合外科杂志,2008,14(2):141-143.
    [59]马卫国,贾金铭,焦拥政等.癃必消胶囊对体外培养的人前列腺增生间质细胞Fibronectin和Collagen IV基因表达的影响[J].中国男科学杂志,2008,22(2):7-10.
    [60]蒋荣伟,岳宗相,王久源等.桂枝茯苓加味汤治疗良性前列腺增生症[J].现代中西医结合杂志,2008,17(9):1369.
    [61]许国振,崔金涛,严启伟等.决闭胶囊抗实验性前列腺增生的研究[J].中成药,2001,23(10):735-737.
    [62]叶加,李长龄,吴恩融等.IPH抗实验性前列腺增生的研究[J].中国药学杂志,2002,37(12):906-910.
    [63]马清钧,李宏杰,孙曙光等.乾列安胶囊对肾阳亏虚型前列腺增生症影响的研究[J].中医药学刊,2003,21(4):530-531.
    [64]商学军,刘智勇,刘志发等.福施乐治疗良性前列腺增生的临床研究[J].中华男科学杂志,2008,14(3):227-230.
    [65]张凯,杨新宇,张军等.泽桂癃爽胶囊治疗良性前列腺增生疗效和作用机理的初步研究[J].中华泌尿外科杂志,2003,24(6):388-390.
    [66]曹继刚,周安方.仙甲汤对前列腺增生大鼠前列腺细胞调亡率影响的实验研究[J].中国中医药科技,2005,12(1):3.
    [67]Stephan Madersbacher, Anton Ponholzer, Ingrid Berger, etal. Medical Management of BPH:Role of Plant Extracts[J]. European Association of Urology,2007.
    [68]解红武.良性前列腺增生的药物治疗[J].天津药学,2002,14(3):15-17.
    [69]Marks LS, Hess DL, Dorey FJ, etal. Tissue effects of sawpalmetto and fi-nasteride. Use of biopsy cores for insitution quantification of prostatic andro-gens. Urology,2001,57:1005.
    [70]Berges RR, KassenA, SengeT, Treatment of symptomatic benign prostat-ic hyperplasia with beta-sitosterol:an 18-month follow-up. BJU Int,2000,85:842-846.
    [71]Bondarenko B, Walther C, Funk P, etal. Phytomedicine,2003,10(Suppl 4):53-55.
    [72]FransD, PeterB, FernandoC, etal. Evaluation of the clinical benefit of Permixon and Tamsulosin in severe BPH patients PERMAL study sub-set analysis. EuropeanUrology,2004,45:773.
    [73]赵珍东.穗花牡荆提取物对前列腺上皮细胞增殖的抑制作用和促细胞凋亡作用[J].国外医药,2006,21(6):263.
    [74]Hizli F, Uygur MC.A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. Int Urol Nephrol.2007,39(3):879-86.
    [75]朱威,胡福良.花粉治疗前列腺增生的研究进展[J].蜜蜂杂志,2005,12:8-10.
    [76]刘勇,蔡花芳,赵铮蓉等.破壁松花粉及软胶囊抗前列腺增生作用[J].中国医疗前沿,2007,2(22):14-15.
    [77]杨兆钢.芒针治疗前列腺炎和前列腺肥大86例临床观察[J].针灸临床杂志,1994,10(1):23-24.
    [78]李惠芳,杨柏如.针灸治疗23例前列腺增生症[J].中国针灸,1994,14(4):13-15.
    [79]付晓红.针刺配合隔姜灸治疗前列腺增生症.针灸临床杂志[J].1998,14(7):41-42.
    [80]胡九凤,王光明.针灸治疗前列腺肥大[J].针灸临床杂志,2000,16(11):7-8.
    [81]饶芳.点刺至阴穴治疗前列腺增生20例[J].中国针灸,2000,20(9):572.
    [82]郭绮云.针灸治疗老年前列腺增生34例疗效观察[J].中国针灸,2001,21(7):389-390.
    [83]陈蓓琳,黄文燕,张载义.骶部俞穴深剌为主治疗良性前列腺增生的临床观察[J].针灸临床杂志,2005,21(9):26-27.
    [84]杨焱,陈红涛.针刺治疗前列腺增生60例分析[J].实用中医内科杂志,2004,18(3):269-270.
    [85]杨运宽,敖有光,胡幼平.针刺治疗老年前列腺增生症37例[J].上海针灸杂志,2005,24(2):19-20.
    [86]史江峰.针刺足厥阴经穴治疗前列腺增生症临床研究[J].辽宁中医杂志,2005,32(12):1295-1296.
    [87]刘鸿.芒针为主治疗前列腺增生症临床观察[J].针灸临床杂志,2005,21(7):19.
    [88]王子臣,王占平,张冰.芒针为主治疗前列腺增生症41例[J].上海针灸杂志,2002,21(3):13-14.
    [89]肖远辉.温针灸为主治疗前列腺增生症疗效观察[J].天津中医学院学报,2002,21(1):20.
    [90]杨春光,廖明霞.针刺加艾灶灸治疗肾阳虚型前列腺增生50例[J]·中国针灸,2004,24(11):752.
    [91]张志荣,成润娣.针药治疗前列腺肥大36例[J].陕西中医,1994,15(4):174.
    [92]张希荣,艾淑滨,范求实等.电针配合竹叶石膏汤加减治疗前列腺肥大症38例临床报告[J].针灸临床杂志,1997,13(3):17.
    [93]邱林.内服中药合针灸治疗前列腺肥大28例[J].国医论坛,1997,12(3):40-41.
    [94]吴昌宏,石绍伟,张志山.针药结合治疗前列腺肥大30例[J].针灸临床杂志,1998,14(9):15.
    [95]赵跃红.加味壮元汤治疗前列腺增生症62例[J].湖南中医杂志,2004,20(3):54.
    [96]何金柱,李兰英,徐伟.辨证取穴论治前列腺增生症[J].针刺研究,2000,25(4):300-301.
    [97]黄志华,陈凯奋.耳穴电针治疗老年性前列腺增生12例[J].中国针灸,1997,17(6):34.
    [98]路变珍,孙润宝.芒针加耳穴埋针治疗前列腺增生症14例[J].针灸临床杂志,1997,13(12):27-28.
    [99]张耕田.耳针治疗前列腺增生症14例[J].中国针灸,1998,18(5):316.
    [100]汤秀芳.耳针配合超声红外光子治疗前列腺增生临床观察[J].中国针灸,2000,20(9):531-2.
    [101]王祥福,王建德,冯志庆.电磁针治疗前列腺增生症60例[J].陕西中医,1993,14(4):174-175.
    [102]刘艳清,易似红.微波针炙仪治疗前列腺增生症30例观察[J].湖南中医学院学报,1995,15(1):62-63.
    [103]高维滨,白彦龙,曹蠹.电针治疗前列腺增生症41例[J].针灸临床杂志,2005,21(5):46-47.
    [104]朱宇丹.针刺配合药灸贴治疗前列腺增生[J].针灸临床杂志,2004,20(10):16-7
    [105]刘志顺,刘元石,杨中阳,等.电针治疗症状性良性前列腺增生[J].中国临床医生,2002,30(2):36-37.
    [106]于向华,高维滨,李傲阳.针刺次髎、中髎穴治疗前列腺增生尿潴留的疗效观察[J].针灸临床杂志,2005,21(4):48-49.
    [107]朱秀平,黄少姬.电磁疗合温针灸治疗前列腺增生61例疗效观察[J].上海针灸杂志,2006,25(5):24-25.
    [108]陈建平.氦氖激光治疗前列腺增生及前列腺炎64例[J].新中医,1993,25(5):37.
    [109]许维新,刘传瑾,伊静秋.电激光针治疗前列腺肥大90例[J].中国针灸,1991,11(6):3.
    [110]马仁海,张丽梅,冀萍等.激光针灸治疗前列腺增生症132例临床观察[J].中国中医药科技,1996,3(2):35.
    [111]洪文,莫飞智,李建强.650hm激光穴位照射与针刺治疗良性前列腺增生症的疗效对比观察[J].激光生物学报,2007,16(2):230-233.
    [112]中华人民共和国卫生部.中药新药临床研究指导原则.第1辑.13:171-17.
    [113]石美鑫.实用外科学.下册.第1版.北京:人民卫生出版,1995:1729-1731.
    [114]郭云绮.针灸治疗老年前列腺增生34例临床观察[J].中国针灸,2001,21(7):389.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700